Latest Conference Articles

June 17th 2018, 1:03am

European Hematology Association Congress

Quizartinib reduced the risk of death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.

June 16th 2018, 9:34pm

European Hematology Association Congress

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

June 16th 2018, 8:27pm

European Hematology Association Congress

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.

June 16th 2018, 7:14pm

European Hematology Association Congress

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the results of quizartinib in patients with relapsed/refractory acute myeloid leukemia.

June 16th 2018, 4:43pm

European Hematology Association Congress

Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

June 16th 2018, 1:59am

European Hematology Association Congress

A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.

June 15th 2018, 11:07pm

European Hematology Association Congress

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses the results of brentuximab vedotin (Adcetris) plus ESHAP followed by autologous stem cell transplant in patients with relapsed/refractory Hodgkin lymphoma.

June 15th 2018, 10:59pm

European Hematology Association Congress

Susan E. Prockop, MD, pediatric oncologist, Memorial Sloan Kettering Cancer Center, discusses tabelecleucel in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphomas.

June 15th 2018, 7:33pm

European Hematology Association Congress

PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.

June 15th 2018, 7:32pm

European Hematology Association Congress

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

June 5th 2018, 9:08am

ASCO Annual Meeting

The combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel educed the risk of death by 22% compared with bevacizumab and chemotherapy in patients with advanced wild-type non-squamous non–small cell lung cancer.

June 5th 2018, 4:44am

ASCO Annual Meeting

Gilberto Lopes, MD, a medical oncologist at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses findings from the KEYNOTE-042 trial of frontline pembrolizumab (Keytruda) as a treatment for patients with squamous and nonsquamous non–small cell lung cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.

June 5th 2018, 3:50am

ASCO Annual Meeting

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses findings from the phase I LIBRETTO-001 study exploring the highly selective RET inhibitor LOXO-292 in patients with RET-altered solid tumors.

June 5th 2018, 12:28am

ASCO Annual Meeting

A combination of 2 over-the-counter medicines can moderately reduce the risk for high-grade dysplasia or esophageal cancer in patients with Barrett’s esophagus if taken for at least 7 years.

June 5th 2018, 12:28am

ASCO Annual Meeting

Combining the CD122-biased cytokine NKTR-214 with the PD-1 inhibitor nivolumab (Opdivo) showed promising antitumor activity, particularly in PD-L1–negative patients.

June 4th 2018, 10:49pm

ASCO Annual Meeting

A 4-drug chemotherapy combination dramatically improved survival compared with standard gemcitabine as postoperative therapy for patients with resected pancreatic cancer.

June 4th 2018, 10:47pm

ASCO Annual Meeting

The PD-1 inhibitor cemiplimab induced an overall response rate of 47.5% in patients with metastatic cutaneous squamous cell carcinoma.

June 4th 2018, 9:20pm

ASCO Annual Meeting

Preoperative treatment with chemotherapy and radiation improved overall survival rates for patients with resectable or borderline resectable pancreatic cancer compared with immediate surgery.

June 4th 2018, 8:50pm

ASCO Annual Meeting

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

June 4th 2018, 8:19pm

ASCO Annual Meeting

Lisocabtagene maraleucel (JCAR017; liso-cel) demonstrated a durable complete remission rate of 46% at 6 months for patients with high-risk diffuse large B-cell lymphoma.